Curis Inc (CRIS) 3.57 $CRIS
Curis (CRIS) Worth Watching: Stock Moves Up 5.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jun 29, 7:51AM CDT
Curis, Inc. (CRIS) was a big mover last session, as its shares rose almost 6% on the day.
CRIS: 3.57 (+0.12), CBM: 49.61 (-0.33)
The Makings Of A Biotech Bubble
Bret Jensen - at Seeking Alpha - Wed Jun 17, 12:06PM CDT
AGEN: 8.95 (-0.29), CRIS: 3.57 (+0.12), TTPH: 49.94 (-0.49), XBI: 265.02 (-2.52), IBB: 393.75 (-0.60), ABBV: 70.52 (-0.04), EGRX: 94.17 (+0.76), PRTA: 66.80 (-0.50), CELG: 139.01 (+0.75)
Curis to Present CUDC-907 Clinical Data at the 20th Congress of the European Hematology Association and the 13th International Congress on Malignant Lymphoma
GlobeNewswire - Wed Jun 10, 6:00AM CDT
Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, today announced that data for CUDC-907 will be presented at the 20 Congress of the European Hematology Association (EHA), being held from June 11 - June 14, 2015 in Vienna, Austria as well as at the 13 International Congress on Malignant Lymphoma (ICML), being held from June 17 - June 20, 2015 in Lugano, Switzerland.
CRIS: 3.57 (+0.12)
Refractory Multiple Myeloma Pipeline Review, H1 2015 - 47 Companies & 68 Drug Profiles
M2 - Mon Jun 08, 10:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dhs6gh/refractory) has announced the addition of the "Refractory Multiple Myeloma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Refractory Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Refractory Multiple Myeloma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 4SC AG - AbbVie Inc. - Acceleron Pharma, Inc. - Acetylon Pharmaceuticals, Inc. - Actinium Pharmaceuticals, Inc. - Altor BioScience Corporation - Arno Therapeutics, Inc. - Array BioPharma Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - Biotest AG - Bristol-Myers Squibb Company - Celgene Corporation - Cellectar Biosciences, Inc. - Chroma Therapeutics Ltd. - CureTech Ltd. - Curis, Inc. - Dicerna Pharmaceuticals, Inc. - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline plc - Immunomedics, Inc. - Johnson & Johnson - Karyopharm Therapeutics, Inc. - MedImmune, LLC - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - MorphoSys AG - Novartis AG - Oncolytics Biotech Inc. - Oncopeptides AB - Onyx Pharmaceuticals, Inc. - Patrys Limited - Pfizer Inc. - Pharma Mar, S.A. For more information visit http://www.researchandmarkets.com/research/dhs6gh/refractory
CLRB: 3.31 (-0.08), CRIS: 3.57 (+0.12), IMMU: 3.75 (-0.07), ONCY: 0.61 (-0.03), DRNA: 13.69 (-0.52), PFE: 34.78 (-0.10), GSK: 42.00 (-0.30), BMY: 68.24 (-1.13), JNJ: 100.20 (+0.02), ATNM: 2.38 (-0.03), MRK: 58.07 (-0.06), ABBV: 70.52 (-0.04), NVS: 103.05 (+1.75), KPTI: 22.95 (-0.26), EXEL: 5.88 (-0.43), XLRN: 31.50 (-0.68), ARRY: 6.59 (-0.06), CELGZ: 2.20 (-0.09)
Curis Up 6.3%, Shares Break Through Resistance (CRIS)
Comtex SmarTrend(R) - Tue Jun 02, 11:46AM CDT
Curis (NASDAQ:CRIS) is one of today's best performing low-priced stocks, up 6.3% to $3.52 on 1.1x average daily volume. Thus far today, Curis has traded 693,000 shares, vs. average volume of 639,000 shares per day. The stock has outperformed the Dow (6.3% to the Dow's 0.2%) and outperformed the S&P 500 (6.3% to the S&P's 0.1%) during today's trading.
CRIS: 3.57 (+0.12)
Curis Reports CUDC-907 Data From the Ongoing Phase 1 Trial at the 2015 ASCO Annual Meeting
GlobeNewswire - Sun May 31, 8:00AM CDT
--CUDC-907 (HDAC and PI3K Inhibitor) Demonstrates Objective Responses, Including
CRIS: 3.57 (+0.12)
Curis to Present at the Jefferies 2015 Healthcare Conference
GlobeNewswire - Wed May 27, 6:00AM CDT
Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, today announced that Dr. Ali Fattaey, President and Chief Executive Officer, will present at the Jefferies 2015 Healthcare Conference, June 3, 2015, at 2:00 p.m. Eastern Time in New York City.
CRIS: 3.57 (+0.12)
Biotech Weekly: Tracking Institutional Money Flow Into ASCO
Daniel Ward - at Seeking Alpha - Tue May 26, 7:37AM CDT
CRIS: 3.57 (+0.12), XBI: 265.02 (-2.52), IBB: 393.75 (-0.60), XNCR: 23.91 (-0.52), ONTY: 3.60 (-0.03), PBYI: 98.75 (-1.25)
Curis Announces Presentations of CUDC-907 and Erivedge(R) Clinical Data at 2015 ASCO Annual Meeting
GlobeNewswire - Wed May 20, 6:00AM CDT
Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, today announced that clinical data from two programs will be presented at the Annual Meeting of American Society of Clinical Oncology (ASCO), being held from May 29 - June 2, 2015 in Chicago, IL.
CRIS: 3.57 (+0.12)
Curis' (CRIS) CEO Ali Fattaey on Q1 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu May 07, 9:10PM CDT
CRIS: 3.57 (+0.12)
Curis reports Q1 results
Seeking Alpha - at Seeking Alpha - Thu May 07, 9:44AM CDT
CRIS: 3.57 (+0.12)
Curis reports 1Q loss
Automated Insights - Thu May 07, 8:39AM CDT
LEXINGTON, Mass. (AP) _ Curis Inc. (CRIS) on Thursday reported a loss of $31.8 million in its first quarter.
CRIS: 3.57 (+0.12)
Curis (CRIS) Q1 2015 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu May 07, 7:25AM CDT
CRIS: 3.57 (+0.12)
Curis EPS of -$0.30
Seeking Alpha - at Seeking Alpha - Thu May 07, 6:06AM CDT
CRIS: 3.57 (+0.12)
Curis Reports First Quarter 2015 Financial Results
GlobeNewswire - Thu May 07, 6:02AM CDT
Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, today reported its financial results for the first quarter ended March 31, 2015.
CRIS: 3.57 (+0.12)
Notable earnings before Thursday’s open
Seeking Alpha - at Seeking Alpha - Wed May 06, 4:30PM CDT
LXP: 8.53 (-0.13), DNOW: 19.62 (+0.95), HL: 2.08 (-0.18), CCOI: 32.12 (-0.12), AAON: 22.60 (-0.41), LQDT: 9.59 (-0.01), CNQ: 23.62 (-0.21), INXN: 27.71 (-0.01), CNK: 39.49 (-0.95), AXAS: 1.97 (+0.01), MG: 18.01 (-0.45), DFT: 30.02 (-0.12), INSY: 44.25 (+0.42), APO: 20.70 (-0.51), FIG: 7.22 (-0.05), MFC: 17.55 (-0.38), GSM: 16.01 (-0.73), LEAF: 50.14 (-1.30), KATE: 19.81 (+0.17), AEE: 38.27 (-0.39), ACRE: 11.89 (-0.09), HII: 114.84 (+0.14), CHD: 84.78 (-0.33), CECE: 9.43 (-0.31), COT: 10.82 (-0.15), AKRX: 46.01 (+0.32), ALU: 3.56 (+0.02), COTY: 27.21 (-0.10), GOLD: 58.31 (-1.92), IT: 86.67 (-0.37), AMRC: 6.66 (-0.29), HILL: 6.25 (+0.09), ARCP: 8.59 (-0.10), CRIS: 3.57 (+0.12), BDX: 148.17 (+0.16), ENZY: 8.16 (+0.06), CCC: 17.32 (-0.49), CSIQ: 25.67 (-0.17), CDW: 34.23 (+0.03), IRC: 9.71 (-0.19), ALE: 45.66 (-1.28), APA: 47.35 (+0.03), HPT: 28.08 (-0.81), CBB: 3.85 (-0.04), LIOX: 5.86 (+0.08), CNSL: 20.21 (+0.03), LPI: 9.49 (-0.22), FSYS: 6.50 (-0.18), GOGO: 19.33 (+0.26), GLP: 32.62 (-1.88), ACHN: 8.97 (-0.12), DWRE: 72.38 (-1.38), CONE: 30.66 (-0.33), BDBD: 6.93 (-0.15), AGIO: 118.42 (+1.04), ARIA: 8.05 (-0.18), BABA: 83.88 (-0.27)
Curis to Release First Quarter 2015 Financial Results and Hold Conference Call on May 7, 2015
GlobeNewswire - Thu Apr 30, 6:00AM CDT
Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, today announced that the Company will release its first quarter 2015 financial results on Thursday, May 7, 2015, before the U.S. financial markets open. The Company's management will also host a conference call on the same day at 8:30 a.m. EDT to review: (i) its proprietary clinical development programs, including CUDC-907, (ii) programs under its collaboration with Aurigene, and (iii) its partnered program, Erivedge(R) (vismodegib). The Company's management will also review its financial results as of and for the first quarter ended March 31, 2015.
CRIS: 3.57 (+0.12)
After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Apr 28, 4:38PM CDT
CANF: 2.01 (+0.04), CRIS: 3.57 (+0.12), SSYS: 33.63 (+0.76), AMCC: 5.93 (+0.05), WYNN: 104.30 (+3.05), CLF: 2.77 (+0.30), BWLD: 171.86 (-2.60), INAP: 9.67 (-0.16), IG: 6.78 (-0.11), XPO: 44.11 (-1.96)
Curis Presents Preclinical Data on CUDC-427 at AACR Annual Meeting
GlobeNewswire - Wed Apr 22, 7:15AM CDT
Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, announced today data presented from in vitro and in vivo studies for CUDC-427, an antagonist of inhibitor of apoptosis (IAP) proteins, at the American Association for Cancer Research (AACR) 2015 Annual Meeting. CUDC-427 is being studied in a Phase 1 trial in patients with advanced solid tumors or lymphoma. Curis' collaborator, Aurigene Discovery Technologies Limited, also reported preclinical data on its interleukin-1 receptor association kinase-4 (IRAK-4) inhibitor program at AACR.
CRIS: 3.57 (+0.12), RDY: 61.74 (+0.26)
Aurigene to Present its NAMPT and IRAK-4 Inhibitors Programs at AACR 2015
PR Newswire - Sat Apr 18, 7:00AM CDT
Aurigene and its partner Curis, Inc. (NASDAQ: CRIS) will be presenting data at the poster sessions from two programs at the American Associate of Cancer Research Annual Meeting (April 18-22 in Philadelphia, PA).
CRIS: 3.57 (+0.12)
Curis (CRIS) Worth Watching: Stock Moves Up 5.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jun 29, 7:51AM CDT
Curis, Inc. (CRIS) was a big mover last session, as its shares rose almost 6% on the day.
CRIS: 3.57 (+0.12), CBM: 49.61 (-0.33)
The Makings Of A Biotech Bubble
Bret Jensen - at Seeking Alpha - Wed Jun 17, 12:06PM CDT
AGEN: 8.95 (-0.29), CRIS: 3.57 (+0.12), TTPH: 49.94 (-0.49), XBI: 265.02 (-2.52), IBB: 393.75 (-0.60), ABBV: 70.52 (-0.04), EGRX: 94.17 (+0.76), PRTA: 66.80 (-0.50), CELG: 139.01 (+0.75)
Curis to Present CUDC-907 Clinical Data at the 20th Congress of the European Hematology Association and the 13th International Congress on Malignant Lymphoma
GlobeNewswire - Wed Jun 10, 6:00AM CDT
Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, today announced that data for CUDC-907 will be presented at the 20 Congress of the European Hematology Association (EHA), being held from June 11 - June 14, 2015 in Vienna, Austria as well as at the 13 International Congress on Malignant Lymphoma (ICML), being held from June 17 - June 20, 2015 in Lugano, Switzerland.
CRIS: 3.57 (+0.12)
Refractory Multiple Myeloma Pipeline Review, H1 2015 - 47 Companies & 68 Drug Profiles
M2 - Mon Jun 08, 10:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/dhs6gh/refractory) has announced the addition of the "Refractory Multiple Myeloma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Refractory Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Refractory Multiple Myeloma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - 4SC AG - AbbVie Inc. - Acceleron Pharma, Inc. - Acetylon Pharmaceuticals, Inc. - Actinium Pharmaceuticals, Inc. - Altor BioScience Corporation - Arno Therapeutics, Inc. - Array BioPharma Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - Biotest AG - Bristol-Myers Squibb Company - Celgene Corporation - Cellectar Biosciences, Inc. - Chroma Therapeutics Ltd. - CureTech Ltd. - Curis, Inc. - Dicerna Pharmaceuticals, Inc. - Exelixis, Inc. - F. Hoffmann-La Roche Ltd. - GlaxoSmithKline plc - Immunomedics, Inc. - Johnson & Johnson - Karyopharm Therapeutics, Inc. - MedImmune, LLC - Merck & Co., Inc. - Millennium Pharmaceuticals, Inc. - MorphoSys AG - Novartis AG - Oncolytics Biotech Inc. - Oncopeptides AB - Onyx Pharmaceuticals, Inc. - Patrys Limited - Pfizer Inc. - Pharma Mar, S.A. For more information visit http://www.researchandmarkets.com/research/dhs6gh/refractory
CLRB: 3.31 (-0.08), CRIS: 3.57 (+0.12), IMMU: 3.75 (-0.07), ONCY: 0.61 (-0.03), DRNA: 13.69 (-0.52), PFE: 34.78 (-0.10), GSK: 42.00 (-0.30), BMY: 68.24 (-1.13), JNJ: 100.20 (+0.02), ATNM: 2.38 (-0.03), MRK: 58.07 (-0.06), ABBV: 70.52 (-0.04), NVS: 103.05 (+1.75), KPTI: 22.95 (-0.26), EXEL: 5.88 (-0.43), XLRN: 31.50 (-0.68), ARRY: 6.59 (-0.06), CELGZ: 2.20 (-0.09)
Curis Up 6.3%, Shares Break Through Resistance (CRIS)
Comtex SmarTrend(R) - Tue Jun 02, 11:46AM CDT
Curis (NASDAQ:CRIS) is one of today's best performing low-priced stocks, up 6.3% to $3.52 on 1.1x average daily volume. Thus far today, Curis has traded 693,000 shares, vs. average volume of 639,000 shares per day. The stock has outperformed the Dow (6.3% to the Dow's 0.2%) and outperformed the S&P 500 (6.3% to the S&P's 0.1%) during today's trading.
CRIS: 3.57 (+0.12)
Curis Reports CUDC-907 Data From the Ongoing Phase 1 Trial at the 2015 ASCO Annual Meeting
GlobeNewswire - Sun May 31, 8:00AM CDT
--CUDC-907 (HDAC and PI3K Inhibitor) Demonstrates Objective Responses, Including
CRIS: 3.57 (+0.12)
Curis to Present at the Jefferies 2015 Healthcare Conference
GlobeNewswire - Wed May 27, 6:00AM CDT
Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, today announced that Dr. Ali Fattaey, President and Chief Executive Officer, will present at the Jefferies 2015 Healthcare Conference, June 3, 2015, at 2:00 p.m. Eastern Time in New York City.
CRIS: 3.57 (+0.12)
Biotech Weekly: Tracking Institutional Money Flow Into ASCO
Daniel Ward - at Seeking Alpha - Tue May 26, 7:37AM CDT
CRIS: 3.57 (+0.12), XBI: 265.02 (-2.52), IBB: 393.75 (-0.60), XNCR: 23.91 (-0.52), ONTY: 3.60 (-0.03), PBYI: 98.75 (-1.25)
Curis Announces Presentations of CUDC-907 and Erivedge(R) Clinical Data at 2015 ASCO Annual Meeting
GlobeNewswire - Wed May 20, 6:00AM CDT
Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, today announced that clinical data from two programs will be presented at the Annual Meeting of American Society of Clinical Oncology (ASCO), being held from May 29 - June 2, 2015 in Chicago, IL.
CRIS: 3.57 (+0.12)
Curis' (CRIS) CEO Ali Fattaey on Q1 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu May 07, 9:10PM CDT
CRIS: 3.57 (+0.12)
Curis reports Q1 results
Seeking Alpha - at Seeking Alpha - Thu May 07, 9:44AM CDT
CRIS: 3.57 (+0.12)
Curis reports 1Q loss
Automated Insights - Thu May 07, 8:39AM CDT
LEXINGTON, Mass. (AP) _ Curis Inc. (CRIS) on Thursday reported a loss of $31.8 million in its first quarter.
CRIS: 3.57 (+0.12)
Curis (CRIS) Q1 2015 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu May 07, 7:25AM CDT
CRIS: 3.57 (+0.12)
Curis EPS of -$0.30
Seeking Alpha - at Seeking Alpha - Thu May 07, 6:06AM CDT
CRIS: 3.57 (+0.12)
Curis Reports First Quarter 2015 Financial Results
GlobeNewswire - Thu May 07, 6:02AM CDT
Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, today reported its financial results for the first quarter ended March 31, 2015.
CRIS: 3.57 (+0.12)
Notable earnings before Thursday’s open
Seeking Alpha - at Seeking Alpha - Wed May 06, 4:30PM CDT
LXP: 8.53 (-0.13), DNOW: 19.62 (+0.95), HL: 2.08 (-0.18), CCOI: 32.12 (-0.12), AAON: 22.60 (-0.41), LQDT: 9.59 (-0.01), CNQ: 23.62 (-0.21), INXN: 27.71 (-0.01), CNK: 39.49 (-0.95), AXAS: 1.97 (+0.01), MG: 18.01 (-0.45), DFT: 30.02 (-0.12), INSY: 44.25 (+0.42), APO: 20.70 (-0.51), FIG: 7.22 (-0.05), MFC: 17.55 (-0.38), GSM: 16.01 (-0.73), LEAF: 50.14 (-1.30), KATE: 19.81 (+0.17), AEE: 38.27 (-0.39), ACRE: 11.89 (-0.09), HII: 114.84 (+0.14), CHD: 84.78 (-0.33), CECE: 9.43 (-0.31), COT: 10.82 (-0.15), AKRX: 46.01 (+0.32), ALU: 3.56 (+0.02), COTY: 27.21 (-0.10), GOLD: 58.31 (-1.92), IT: 86.67 (-0.37), AMRC: 6.66 (-0.29), HILL: 6.25 (+0.09), ARCP: 8.59 (-0.10), CRIS: 3.57 (+0.12), BDX: 148.17 (+0.16), ENZY: 8.16 (+0.06), CCC: 17.32 (-0.49), CSIQ: 25.67 (-0.17), CDW: 34.23 (+0.03), IRC: 9.71 (-0.19), ALE: 45.66 (-1.28), APA: 47.35 (+0.03), HPT: 28.08 (-0.81), CBB: 3.85 (-0.04), LIOX: 5.86 (+0.08), CNSL: 20.21 (+0.03), LPI: 9.49 (-0.22), FSYS: 6.50 (-0.18), GOGO: 19.33 (+0.26), GLP: 32.62 (-1.88), ACHN: 8.97 (-0.12), DWRE: 72.38 (-1.38), CONE: 30.66 (-0.33), BDBD: 6.93 (-0.15), AGIO: 118.42 (+1.04), ARIA: 8.05 (-0.18), BABA: 83.88 (-0.27)
Curis to Release First Quarter 2015 Financial Results and Hold Conference Call on May 7, 2015
GlobeNewswire - Thu Apr 30, 6:00AM CDT
Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, today announced that the Company will release its first quarter 2015 financial results on Thursday, May 7, 2015, before the U.S. financial markets open. The Company's management will also host a conference call on the same day at 8:30 a.m. EDT to review: (i) its proprietary clinical development programs, including CUDC-907, (ii) programs under its collaboration with Aurigene, and (iii) its partnered program, Erivedge(R) (vismodegib). The Company's management will also review its financial results as of and for the first quarter ended March 31, 2015.
CRIS: 3.57 (+0.12)
After Hours Gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Apr 28, 4:38PM CDT
CANF: 2.01 (+0.04), CRIS: 3.57 (+0.12), SSYS: 33.63 (+0.76), AMCC: 5.93 (+0.05), WYNN: 104.30 (+3.05), CLF: 2.77 (+0.30), BWLD: 171.86 (-2.60), INAP: 9.67 (-0.16), IG: 6.78 (-0.11), XPO: 44.11 (-1.96)
Curis Presents Preclinical Data on CUDC-427 at AACR Annual Meeting
GlobeNewswire - Wed Apr 22, 7:15AM CDT
Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, announced today data presented from in vitro and in vivo studies for CUDC-427, an antagonist of inhibitor of apoptosis (IAP) proteins, at the American Association for Cancer Research (AACR) 2015 Annual Meeting. CUDC-427 is being studied in a Phase 1 trial in patients with advanced solid tumors or lymphoma. Curis' collaborator, Aurigene Discovery Technologies Limited, also reported preclinical data on its interleukin-1 receptor association kinase-4 (IRAK-4) inhibitor program at AACR.
CRIS: 3.57 (+0.12), RDY: 61.74 (+0.26)
Aurigene to Present its NAMPT and IRAK-4 Inhibitors Programs at AACR 2015
PR Newswire - Sat Apr 18, 7:00AM CDT
Aurigene and its partner Curis, Inc. (NASDAQ: CRIS) will be presenting data at the poster sessions from two programs at the American Associate of Cancer Research Annual Meeting (April 18-22 in Philadelphia, PA).
CRIS: 3.57 (+0.12)
